Table 2.
Multi-cohort analysis.
| Vaccination age (years) | HPV vaccine doses needed | HPV-related cancer cases prevented - Total | HPV-related cancer cases prevented – Average per cohort | QALY gained – Total * | QALY gained– Average per cohort* | Average cost difference vaccination versus no vaccination | ICER vaccination strategy vs no male vaccination |
|---|---|---|---|---|---|---|---|
| 12 | 60,000 | 56 | 56 | 205 | 205 | €3,672,920 | €17,907 |
| 12–14 | 180,000 | 166 | 55 | 606 | 202 | €3,674,536 | €18,197 |
| 12–16 | 360,000 | 275 | 55 | 1005 | 201 | €4,434,494 | €22,109 |
| 12–26 | 1,260,000 | 720 | 48 | 2568 | 172 | €5,219,633 | €32,256 |
ICER: incremental cost-effectiveness ratio, HPV: human papillomavirus, QALY: quality-adjusted life year. The ICER is based on the average ICER of age cohorts and thus based on non-rounded QALY estimates. *Rounded.